Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 18/20 | 0.79 |
| ▸ | MMP2 | P08253 | 8/20 | 0.79 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.68 |
| ▸ | MMP13 | P45452 | 2/20 | 0.68 |
| ▸ | ADAMTS1 | Q9UHI8 | 1/20 | 0.68 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20708281 | 0.89 | ADAMTS5 (0.79) | ADAMTS5MMP2ADAMTS4MMP13ADAMTS1 | |
| SCHEMBL20708557 | 0.89 | ADAMTS5 (0.77) | ADAMTS5MMP2ADAMTS4MMP13ADAMTS1 | |
| SCHEMBL17884860 | 0.88 | ADAMTS5 (1.00) | ADAMTS5MMP2 | |
| SCHEMBL20708428 | 0.86 | ADAMTS5 (0.77) | ADAMTS5MMP2ADAMTS4MMP13ADAMTS1 | |
| SCHEMBL21582785 | 0.86 | ADAMTS5 (0.79) | ADAMTS5MMP2ADAMTS4MMP13ADAMTS1 | |
| SCHEMBL21582762 | 0.86 | ADAMTS5 (0.79) | ADAMTS5MMP2ADAMTS4MMP13ADAMTS1 | |
| SCHEMBL21582760 | 0.85 | MMP2 (0.78) | ADAMTS5MMP2ADAMTS4MMP13ADAMTS1 | |
| SCHEMBL20708570 | 0.85 | ADAMTS5 (0.77) | ADAMTS5MMP2ADAMTS4MMP13ADAMTS1 | |
| SCHEMBL20708283 | 0.84 | ADAMTS5 (0.80) | ADAMTS5MMP2ADAMTS4MMP13ADAMTS1 | |
| SCHEMBL20708451 | 0.84 | ADAMTS5 (0.79) | ADAMTS5MMP2ADAMTS4MMP13ADAMTS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-10-07 | — | — | US | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | ADAMTS5 2/4885MMP2 53/4885ADAMTS4 4/4885 |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | ADAMTS5 2/4885MMP2 53/4885ADAMTS4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.